<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: GTPase regulator associated with the focal <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> kinase (GRAF), a putative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene, is found inactivated in <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e> by either genetic or epigenetic abnormalities </plain></SENT>
<SENT sid="1" pm="."><plain>However, the expression level of GRAF gene has not yet been studied in <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to investigate the expression level of GRAF gene in those patients with <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> including <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The expression levels of GRAF transcript were determined in 94 patients using real-time quantitative PCR (RQ-PCR) </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical and laboratory data of these patients were collected and analyzed </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The significantly decreased level of GRAF transcript was observed in three <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> compared to controls </plain></SENT>
<SENT sid="6" pm="."><plain>Within <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, there was no difference in the level of GRAF transcript among different FAB subtypes (P &gt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Difference was not observed in the amount of GRAF <z:chebi fb="2" ids="33699">mRNA</z:chebi> between <z:mp ids='MP_0005481'>CML</z:mp> at <z:hpo ids='HP_0011010'>chronic</z:hpo> phase and controls </plain></SENT>
<SENT sid="8" pm="."><plain>As <z:mp ids='MP_0005481'>CML</z:mp> progressed, GRAF transcript significantly decreased </plain></SENT>
<SENT sid="9" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, three cases with 5q deletion had lower GRAF transcript than four without 5q deletion (median 0.76 vs 2.99) (P &gt; 0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: our results demonstrate that the GRAF transcript is decreased in <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
</text></document>